Merrimack Pharmaceuticals, Inc.;The Regents of the University of California
发明人:
MARKS, James D.,DRUMMOND, Daryl,GEDDIE, Melissa,KIRPOTIN, Dmitri,KOHLI, Neeraj,LUGOVSKY, Alexey
申请号：
EP17767295
公开号：
EP3429624A4
申请日:
2017.03.13
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
Provided by the present disclosure are antibodies (e.g., scFvs) that include CDRs and human framework regions that confer useful properties upon the antibodies. In certain embodiments, such properties include thermostability (e.g., increased melting temperature), efficient binding to Staphylococcus aureus Protein A, or both. In certain aspects, the antibodies are internalizing antibodies that specifically bind to the tumor associated antigen EphA2.
